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The Coalition for Epidemic Preparedness Innovations (CEPI) have recently put out a call for proposals aimed at 
platform technologies that can enable rapid vaccine development for novel or previously unrecognized viruses. 
We have proposed a streamlined process for the generation of stabilized subunit vaccines. This project brings 
together unique proprietary recombinant technology for generating stabilized subunit vaccines (the molecular 
clamp), a highly skilled team from some of Australia’s leading scientific organizations and world-class facilities.  
Molecular clamp is a broadly applicable platform technology that facilitates expression of recombinant viral 
glycoproteins in subunit form without loss of native antigenicity. The molecular clamp imparts superior stability 
over alternative trimerization domains, efficiently stabilizing soluble viral fusion proteins in their native trimeric 
'pre-fusion' form. This form is equivalent to that expressed on the virion surface and the principle target for a 
protective neutralizing antibody response. Through stabilization of the pre-fusion form, the molecular clamp 
promotes the production of highly neutralizing and broadly cross-reactive antibodies. Importantly, the molecular 
clamp does not required prior knowledge of a proteins quaternary structure.  
 
The goal of this project is to establish a holistic and robust pipeline to rapidly generate novel subunit vaccines 
purely from sequence information. Within this pipeline, pre-clinical development, including the generation of 
evidence for safety and immunogenicity in animal models, is to be completed within a 16 week window allowing 
candidate vaccines to then progress directly into Phase I clinical trials. Phase I trials, including regulatory 
approval, patient immunization and analysis of safety and immunogenicity will be completed within 10 weeks 
(week 17-26 of the pipeline). As part of the project, large-scale manufacture of >200,000 vaccine doses will be 
completed within a further 8 weeks. Vaccine produced through this pipeline will therefore be available for rapid 
deployment and provide the best possible opportunity to counter emerging viral epidemics. 
 
Figure 1. Overview of rapid response pipeline design. Key pipeline components are designated by color. Yellow: 
Vaccine design and animal immunizations; Red: Vaccine manufacture; Purple: Toxicology analysis; Blue: 
Immunogenicity and animal protection studies; Green Phase I clinical trials. Note: stage III is able to be 
optionally triggered at week 18, prior to completion of stage II. Early triggering of stage III at week 18 in the 
event of a ‘worst case scenario’ will decrease the total time to deployment to 26 weeks from pathogen 
identification. 
